511 related articles for article (PubMed ID: 33416209)
21. New targets for CAR T therapy in hematologic malignancies.
Savani M; Oluwole O; Dholaria B
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
23. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
25. Haematology laboratory parameters to assess efficacy of CD19-, CD22-, CD33-, and CD123-directed chimeric antigen receptor T-cell therapy in haematological malignancies.
Drumheller B; Gebre K; Lockhart B; Margolskee E; Obstfeld A; Paessler M; Pillai V
Int J Lab Hematol; 2022 Aug; 44(4):750-758. PubMed ID: 35419923
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of failure of chimeric antigen receptor T-cell therapy.
Li X; Chen W
Curr Opin Hematol; 2019 Nov; 26(6):427-433. PubMed ID: 31577606
[TBL] [Abstract][Full Text] [Related]
27. Effects of Cannabidiol on the Functions of Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Chantarat N; Pe KCS; Suppipat K; Vimolmangkang S; Tawinwung S
Cannabis Cannabinoid Res; 2024 Jun; 9(3):819-829. PubMed ID: 37878339
[No Abstract] [Full Text] [Related]
28. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
29. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
Zhou D; Zhu X; Xiao Y
Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
[TBL] [Abstract][Full Text] [Related]
30. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
31. CAR-T cells: the Chinese experience.
Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
[TBL] [Abstract][Full Text] [Related]
32. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
Han X; Wang Y; Wei J; Han W
J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
[TBL] [Abstract][Full Text] [Related]
33. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
34. Expanding the role of CAR T-cell therapy: From B-cell hematological malignancies to autoimmune rheumatic diseases.
Shumnalieva R; Velikova T; Monov S
Int J Rheum Dis; 2024 May; 27(5):e15182. PubMed ID: 38742463
[TBL] [Abstract][Full Text] [Related]
35. T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
Janelle V; Rulleau C; Del Testa S; Carli C; Delisle JS
Front Immunol; 2020; 11():276. PubMed ID: 32153583
[TBL] [Abstract][Full Text] [Related]
36. Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
Rotolo A; Karadimitris A; Ruella M
Leuk Lymphoma; 2018 Sep; 59(9):2040-2055. PubMed ID: 29165008
[TBL] [Abstract][Full Text] [Related]
37. The market for chimeric antigen receptor T cell therapies.
Yip A; Webster RM
Nat Rev Drug Discov; 2018 Mar; 17(3):161-162. PubMed ID: 29375140
[No Abstract] [Full Text] [Related]
38. Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
Xie D; Jin X; Sun R; Zhang M; Wang J; Xiong X; Zhang X; Zhao M
Technol Cancer Res Treat; 2022; 21():15330338221118413. PubMed ID: 35989682
[TBL] [Abstract][Full Text] [Related]
39. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J; Wickman E; DeRenzo C; Gottschalk S
Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
[TBL] [Abstract][Full Text] [Related]
40. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
